Company Of The Day: Merck
What?
Merck (NYSE:MRK) is preparing a new formulation for its blockbuster cancer immunotherapy Keytruda, which could be injected under the skin.
Why?
- Pick Either Merck Stock Or Its Peer – Both May Offer Similar Returns
- Is A Fall Imminent For Merck Stock After A 12% Rise In A Month?
- Will Merck Stock Rise After Its Q3 Results?
- Merck Stock Is Likely A Better Pick Over Its Peer
- Is Humira Maker A Better Bet Over Merck Stock?
- Should You Buy Merck Stock After An Upbeat Q2?
Keytruda will see patents start to expire in 2028. Merck believes that the new formulation has the potential to be novel, non-obvious, and useful, implying that it could receive a new patent.
So What?
Keytruda is Merck’s most important drug, generating over $17 billion in sales in 2021. These developments could potentially help the company hold off on a sales decline.
See Our Complete Analysis For Merck
| Returns | Dec 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
| MRK Return | 0% | 44% | 87% |
| S&P 500 Return | 0% | -15% | 82% |
| Trefis Multi-Strategy Portfolio | 1% | -17% | 230% |
[1] Month-to-date and year-to-date as of 12/5/2022
[2] Cumulative total returns since the end of 2016